Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A cohort, multicentre, observational, prospective study of clinical outcomes following ustekinumab induction treatment in Crohn's disease patients

Next Previous
Trial Profile

A cohort, multicentre, observational, prospective study of clinical outcomes following ustekinumab induction treatment in Crohn's disease patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms AURORA

Most Recent Events

  • 20 Jun 2023 New trial record
  • 09 May 2023 Results presented at the Digestive Disease Week 2023
  • 09 May 2023 Results assessing the association of clinical outcomes with baseline serum cytokine and chemokine levels, and faecal microbiome signatures, presented at the Digestive Disease Week 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top